Resistin is a recently discovered signal molecule, which could help elucidation of the pathophysiology of the insulin resistance and its correlation with obesity. As little information was available about resistin determination in venous blood at the time of our study, we focused on the question whether any correlation exists between persons with type 2 diabetes mellitus, with systemic inflammation, healthy persons and resistin concentrations and laboratory markers of inflammation, peptone, BMI. Differences of resistin values in these types of volunteers were studied as well.
INTRODUCTION
The prevalence of type 2 diabetes mellitus reaches 5-6 %. Its relation to obesity is well known (up to 80% of cases). Individuals with type 2 DM mostly show a relative lack of insulin caused by insulin resistance (reduced utilization of glucose in muscles and fat) and lower ability to inhibit gluconeogenesis in liver.
Similarly, obesity is characterized by insulin resistance and increased supply of triacylglycerols in adipose tissue. All these problems are of practical clinical importance 4, 20 . In both cases it has not been explained until Resistin (in addition to leptin and TNF-alpha) seems to be one of promising parameters that could help to elucidate pathophysiology of the origin of insulin resistance and its association with obesity. These parameters have been studied intensively in animal experiments. However, resistin and leptin and TNF-alpha pathophysiology in human seems to be quite different.
RESISTIN -CONCENTRATIONS IN PERSONS WITH TYPE 2 DIABETES MELLITUS AND IN INDIVIDUALS WITH ACUTE INFLAMMATORY DISEASE
With regard to the fact that at the time of our study sporadic information was available about resistin determination in venous blood, we decided to investigate the resistin values and answer the following questions: 1. Persons with sever systemic inflammation a) Does any correlation exist between resistin concentration and inflammation markers? b) Does any relationship exist between the concentration of resistin, leptin and BMI? c) Do resistin values differ from resistin values in the normal population?
2. Persons with type 2 DM treated with oral antidiabetic drugs a) Does any correlation exist between insulin sensitivity markers (HOMA) and resistin concentration? b) Does any correlation exist between BMI and resistin concentration? c) Do resistin values differ from resistin values in the normal population?
METHODS
Persons under study were divided into 3 groups according to the following criteria:
• Group A with clinical signs of inflammatory disease of respiratory tract (bronchitis, bronchopneumonia, pneumonia), leukocytosis > 10000/µl and CRP concentration > 50 mg/l (35 persons).
• Group B with well controlled type 2 DM treated by oral antidiabetic drugs (HbA1c < 7%), without clini- oo -9 oo a.m. following the overnight fasting. The routine biochemical analyses were performed on the day of serum separation. Serum samples for special analyses resistin and leptin were stored at -80 °C in separated aliquots, usually for less than one month.
BMI was determined in all probands. All data were processed statistically using Stagrafics 6.0 ANOVA.
RESULTS
We examined 114 persons and divided them into 3 groups.
Persons with clinical signs of severe inflammation (Group A) had significantly higher serum concentrations of Il6, CRP, resistin and significantly lower BMI, lower values of glucose, sodium, triacylglycerols, cholesterol, LDL-cholesterol, HDL-cholesterol and indexes leptin/resistin as well as resistin/CRP indexes than diabetics of type 2 (Group B) ( Tables 1, 2) .
Persons with clinical signs of severe inflammation (Group A) had significantly higher concentrations of TNF-alpha, Il6, CRP, resistin, glucose, leptin, and considerably lower values of albumin, sodium, HDL-cholesterol and resistin/CRP index compared to healthy volunteers (Group C).
Our patients with signs of severe inflammation (Group A) can be characterized as persons with a significant increase in inflammatory markers, catabolism with hypocholesterolemia and hypoalbuminemia ( Tables 1, 2 Tables 1, 2) .
None of the three groups differed significantly in age or sex (Tables 1, 2, 3) . Table 3 . Significant correlations in the whole group under study.
When investigating a relationship between resistin concentration and other individual parameters, we found in the whole group significant positive correlations with the values of CRP, IL6, TNF-alpha and creatinine, and negative correlations with the values of cholesterol and albumin. No correlation was found between resistin and leptin, resistin and BMI (Table 3) .
Healthy volunteers (Group C) showed a significant correlation between leptin and resistin; this correlation was not found in patients with inflammation or type 2 DM. This group also showed a distinct correlation between leptin and concentrations of cholesterol, magnesium and BMI ( Table 3 ). The group of volunteers with inflammation (Group A) was found to have a significant positive correlation between resistin and inflammatory markers, kalemia, and a negative correlation between resistin and cholesterol. We also recorded positive correlations between leptin and BMI and negative correlations between leptin and CRP (Table 3) .
In persons with type 2 DM (Group B) no significant correlations between resistin and other measured parameters were found. We recorded a distinct positive correlation between leptin and CRP, Il-6 and BMI, and a negative correlation between leptin and glucose in serum (Table 3) .
DISCUSSION
Several years ago, a new signal molecule was discovered and termed resistin (12,5 kDa, according to its effect on insulin resistance). Resistin is a product of RSTN gene that belongs to the category of proteins rich in cysteine; proteins in this category comprise, due to a high homology they are confused: ADSF (Adipose Tissue-Specific Secretory Factor), FIZZ3 (Found in Inflammatory Zone), FIZZ1 (identified for the first time in a bronchoalveolar lavage of the inflammation-altered liver), FIZZ2, RELM-a, RELM-b (resistin like molecule).
Resistin is produced by preadipocytes and adipocytes in the form of a propeptide (108 amino acids); prior to secretion into circulation, it liberates a hydrophobic signal peptide (16 amino acids). Then resistin circulates in the system circulation as a dimer consisting of 92 amino acids, connected by disulfide bridges (mice resistin consists of 114 amino acids).
Occurrence and effects: resistin and resistin-like molecules occur in white adipose tissue, mammary glands, heart, brain, lungs, gastrointestinal tract (it was found that e.g. RELM-b was present in gastrointestinal tract in the are of a high proliferation activity of epithelia, was excessively expressed near tumors -it is supposed to influence proliferation).
With regard to a high homology between RELM and FIZZ it is believed that the effect of both substances is similar. 11 . This is supported by the fact that TZD reduces local production of TNF-a in adipocytes.
Pathophysiology of resistin -human study:
It has not been proved yet whether the above-mentioned relations apply also to human. 1. Resistin expression in adipocytes is low, resistin mostly occurs in mononuclear cells. 2. Differentation of adipocytes is related to decreased resistin expression (reverse effect in mice). 3. Obesity and insulin sensitivity disorder is associated with polymorphism of resistin gene (but no correlation was proved between type 2 DM and gene polymorphism) and obese people have an elevated resistin expression in abdominal adipose tissue (this could indicate relation between resistin and obesity in type 2 DM or risk of IHD), but clinical studies have not proved yet any correlation between resistin gene expression, insulin sensitivity and type 2 DM 15, 10, 14, 16, 7 . 4. It has not been proved yet that a relation between adipocytes and insulin effect is mediated by TNF-a or resistin 10 .
Regulation: Resistin expression is regulated by many hormones and cytokines related to the metabolism of insulin, glucose and adipocyte metabolism in general. Increase: hyperglycemia, hypercortisolism (administration of dexamethasons to mice resulted in elevation of mRNA resistin 2.5-3.5×).
Decrease: GH deficiency (application of GH leads to normalization -increased resistin expression), insulin (insulin is considered to be the main inhibitor of resistin), thiazolindions (effect via PPAr-g (peroxisome proliferator-activated receptor-g). However, TZD decrease mRNA resistin only in obese mice, in thin mice they increase resistin expression -verified on various adipocyte lines), TNF-alpha (up by 80%), adrenalin, androgens, endothelin-1 17, 5, 13, 1, 2, 9 . Expression of resistin in adipose tissue also decreases at lactation (together with leptin expression) 17 .
Measurement of resistin concentration: Most studies did not investigate resistin concentration in serum 7 . A validated diagnostic set for resistin determination was not available at the time of our study; we found only one producer of the diagnostic set for resistin determination, which did not meet the analytical criteria 7 . Analytical characteristics of the set used in this study are commonly used.
In our previous study, resistin concentration ranged from 7.3 to 21.3 ng/ml (x ± 2s) in 123 healthy volunteers without obesity. No correlation was proved between resistin and age, sex or BMI. The values of resistin in healthy probands under the present study (Group C) did not differ from those recorded previously 18 . With regard to the fact that a correlation was found between the concentrations of resistin and leptin in healthy probands (which we did not find in diabetics and persons with severe systemic inflammation), we assume that in healthy individuals there exists a metabolic regulation in which both factors are involved 14 . Persons with inflammation (Group A) can be characterized as probands with significant increase in inflammatory markers and catabolism.
Increased resistin values found in those persons (compared to values in normal population) could be caused by a local effect of inflammatory cytokines on its production (FIZZ analogy) 11 . It is interesting that in the case of severe inflammation, correlation between leptin and resistin concentrations disappears in contrast to healthy individuals where it is present (probably an effect of cytokines).
Persons with type 2 DM are used to develope on atherogenic lipotype, signs of chronic inflammation and a higher risk of atherosclerotic complications. This observation corresponds with our Group B. In these probands the correlation between inflammation markers and resistin concentrations disappers. Persons with type 2 DM have higher CRP concentrations than healthy individuals, but cytokine values are not significantly increased in systemic circulation. This fact may account for no relations between inflammatory markers and resistin concentration observed in acute severe inflammation. It is probable that a "slight" chronic inflammation (e.g. endothelial dysfunction) does not influence significantly resistin concentrations.
Determination of a limits of resistin concentration in human population could answer many questions related to the origin of insulin resistance, despite the fact that resistin function in human still remains unclear (in contract to mice models).
It has not been proved yet that correlation between insulin resistance and resistin exists in humans. Among other questions that should be answered is the existence of the resistin receptor and its location (muscles, brain, liver, etc.).
The analogy between human and mice resistin is not adequate (about 60%); this stimulates further questions and indicates a low stage of sequence similarity among species 8 .
CONCLUSION
We confirmed the existence of a correlation between leptin and resistin concentrations in the serum of a healthy population.
In patients with severe inflammatory disease we found a correlation between resistin concentration in serum and laboratory markers of inflammation (CRP, TNF-alpha, IL6), however, no correlation was found between leptin and resistin.
Resistin concentration in the serum of these patients is significantly higher than in healthy population or in well controlled persons with type 2 DM with signs of insulin resistance. This may be probably explained by a direct effect of inflammatory cytokines on resistin production.
In patients with type 2 DM we found no significant correlations between resistin, insulin sensitivity markers, BMI or leptin. Resistin concentration in patients with type 2 DM does not differ from resistin concentrations of a common population.
